Methotrexate and bone marrow suppression: Standard collaborative care will be made more difficultBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7399.1145-c (Published 22 May 2003) Cite this as: BMJ 2003;326:1145
- A K Clarke, medical director
- Royal National Hospital for Rheumatic Diseases NHS Trust, Bath BA1 1RL
EDITOR—The paper by Sosin et al on low dose methotrexate and bone marrow suppression reminds us that even very safe drugs need to be monitored with a reasonable degree of care.1 Case 2 is almost certainly due to overdosage because of daily dosing rather than weekly dosing. Case 1 seems to be due to the drug alone, and in …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial